Research Papers

25 of 3284 papers

CSV Excel
Quick filters: Open Data Open Code Pre-registered Funding Declared COI Declared Open Access Clear Filters
TSC22D2 Regulates ACOT8 to Delay the Malignant Progression of Colorectal Cancer.
Zhou N; Guo C; Du J; Zhang X; Xu Q; Zheng X; Tu L.
Onco Targets Ther (Unknown)
Published: 2024
3/6 Transparent
Funding Declared
Applications of Yttrium-90 (<sup>90</sup>Y) in Hepatocellular Carcinoma.
Jiang Z; Yang F; Wang W.
Onco Targets Ther (Unknown)
Published: 2024
3/6 Transparent
Funding Declared
Prognostic Factors and Construction of Nomogram Prediction Model of Lung Cancer Patients Using Clinical and Blood Labor…
Zhang Y; Wan W; Shen R; Zhang B; Wang L; Zhang H; Ren X; Cui J; Liu J.
Onco Targets Ther (Unknown)
Published: 2024
3/6 Transparent
Funding Declared
Crosstalk Between circRNA and Tumor Microenvironment of Hepatocellular Carcinoma: Mechanism, Function and Applications.
Xie C; Hao X; Yuan H; Wang C; Sharif R; Yu H.
Onco Targets Ther (Unknown)
Published: 2024
3/6 Transparent
Funding Declared
Inhibition of ATM with KU-55933 Sensitizes Endometrial Cancer Cell Lines to Olaparib.
Zhang A; Zhang L; Xie X; Liu D.
Onco Targets Ther (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Predictive Significance of Systemic Immune-Inflammation Index in Patients with Breast Cancer: A Retrospective Cohort St…
Zhou Y; Guo X; Shen L; Liu K; Sun Q; Wang Y; Wang H; Fu W; Yao Y; Wu S; Chen H; Qiu J; Pan T; Deng Y.
Onco Targets Ther (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Optimizing the Continuum of Care in Gastric Cancer.
Riccò B; Martinelli G; Bardasi C; Dominici M; Spallanzani A; Salati M.
Onco Targets Ther (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Safety and Efficacy Analysis of PD-1 Inhibitors in Combination with Gemcitabine Plus Nab-Paclitaxel for Advanced Pancre…
Chen Z; He Y; Ding C; Chen J; Gu Y; Xiao M; Li Q.
Onco Targets Ther (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Galectin-9 Expression is Correlated to Cervical Squamous Cell Carcinoma Progression and Overall Survival.
Mendieta-Carmona V; Delgado-López G; Reyes-Leyva J; Gutiérrez-Quiroz CT; Vazquez-Zamora VJ; Picazo-Mendoza DA; Montiel-Jarquín AJ; Martinez-Morales LP; Vallejo-Ruiz V.
Onco Targets Ther (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
High <i>BCR::ABL1</i> Expression Defines CD34+ Cells with Significant Alterations in Signal Transduction, Short-Prolife…
Massimino M; Stella S; Tirrò E; Pennisi MS; Stagno F; Vitale SR; Romano C; Tomarchio C; Parrinello NL; Manzella L; Di Raimondo F; Vigneri P.
Onco Targets Ther (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Recent Advances in the Management of Adverse Events Associated with Lorlatinib.
Liao D; Zhang J; Yan T; Chen S; Li W; Shangguan D; She Z.
Onco Targets Ther (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Spotlight on GOT2 in Cancer Metabolism.
Kerk SA; Garcia-Bermudez J; Birsoy K; Sherman MH; Shah YM; Lyssiotis CA.
Onco Targets Ther (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Targeted Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Tafasitamab in Context.
Abdulhaq H; Hwang A; Mahmood O.
Onco Targets Ther (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Clinical Utility of Mobocertinib in the Treatment of NSCLC - Patient Selection and Reported Outcomes.
Arnold A; Ganti AK.
Onco Targets Ther (Unknown)
Published: 2023
2/6 Transparent
Systemic Treatment for Gynecological Cancer Patients Undergoing Hemodialysis.
Zhang N; Liu C; Di W.
Onco Targets Ther (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Exploring the Association Between PRC2 Genes Variants and Lung Cancer Risk in Chinese Han Population.
Gao M; Li Y; Huang H; Fan Y; Shi R; Su L; Chen C; Li X; Zhu G; Wu D; Cao P; Liu H; Chen J; Kang S.
Onco Targets Ther (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Targeting B Cell Maturation Antigen in Patients with Multiple Myeloma: Current Perspectives.
Shrivastava T; Van Rhee F; Al Hadidi S.
Onco Targets Ther (Unknown)
Published: 2023
2/6 Transparent
Esomeprazole Alleviates Cisplatin Resistance by Inhibiting the AKT/mTOR Pathway in Ovarian Cancer Cells.
Duan J; Zhang Z; Du J; Zhang J; Li M; Li C.
Onco Targets Ther (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Spotlight on New Therapeutic Opportunities for MYC-Driven Cancers.
D'Avola A; Kluckova K; Finch AJ; Riches JC.
Onco Targets Ther (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Targeted Treatment of Advanced Endometrial Cancer: Focus on Pembrolizumab.
El-Ghazzi N; Durando X; Giro A; Herrmann T.
Onco Targets Ther (Unknown)
Published: 2023
2/6 Transparent
JUND Promotes Tumorigenesis via Specifically Binding on Enhancers of Multiple Oncogenes in Cervical Cancer.
Zhou J; Mo J; Tan C; Xie F; Liang J; Huang W.
Onco Targets Ther (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
High Expression of Triggering Receptor Expressed on Myeloid Cells 1 Predicts Poor Prognosis in Glioblastoma.
Ma K; Guo Q; Zhang X; Li Y.
Onco Targets Ther (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
The Role of Neutrophil-to-Lymphocyte Ratio in Advanced <i>EGFR</i>-Mutant NSCLC Patients Treated with First-Line Osimer…
Chen KC; Huang YH; Hsu KH; Tseng JS; Chang GC; Yang TY.
Onco Targets Ther (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Potential Therapeutic Targets for Luminal Androgen Receptor Breast Cancer: What We Know so Far.
Stella S; Martorana F; Massimino M; Vitale SR; Manzella L; Vigneri P.
Onco Targets Ther (Unknown)
Published: 2023
2/6 Transparent
Minimal Residual Disease Monitoring in Radically Treated Non-Small Cell Lung Cancer: Challenges and Future Directions.
O'Sullivan HM; Feber A; Popat S.
Onco Targets Ther (Unknown)
Published: 2023
2/6 Transparent